Intelligent Insulin Management Platform

Publication ID: 24-11857314_0008_PTD
Published: November 07, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Intelligent Insulin Management Platform,” Published Technical Disclosure No. 24-11857314_0008_PTD, Published November 07, 2025, available at https://archive.pr1or.art/24-11857314_0008_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,314.

Summary of the Inventive Concept

An innovative system integrating AI, IoT, blockchain, and new materials to optimize insulin administration and improve patient outcomes

Background and Problem Solved

The original patent's insulin management system, while effective, has limitations in data accuracy, security, and patient engagement. The new inventive concept addresses these limitations by incorporating cutting-edge technologies to create a more comprehensive and personalized insulin management platform.

Detailed Description of the Inventive Concept

The Intelligent Insulin Management Platform combines a blockchain-based patient data management module with an AI-driven clinical decision support system, IoT-enabled continuous glucose monitoring, and a cloud-based data analytics platform. This integrated system enables real-time monitoring, personalized insulin dosing, and secure data storage. The platform also features a wearable device with integrated IoT sensors, a natural language processing (NLP) module, and a mobile app for patient engagement.

Novelty and Inventive Step

The new inventive concept's integration of AI, IoT, blockchain, and new materials with the original insulin management system provides a non-obvious and novel approach to optimizing insulin administration. The inventive step lies in the synergistic combination of these distinct technologies to create a more powerful and effective system.

Alternative Embodiments and Variations

Alternative embodiments of the Intelligent Insulin Management Platform could include the use of different AI algorithms, various IoT sensor configurations, or alternative blockchain architectures. Additionally, the platform could be adapted for use in different healthcare settings or for managing other chronic conditions.

Potential Commercial Applications and Market

The Intelligent Insulin Management Platform has significant commercial potential in the healthcare industry, particularly in the areas of diabetes management and personalized medicine. The platform's ability to improve patient outcomes, reduce healthcare costs, and enhance patient engagement makes it an attractive solution for healthcare providers, pharmaceutical companies, and medical device manufacturers.

Field of Art

Medical informatics and digital health technologies focused on insulin management, diabetes care, and patient monitoring systems

Person of Ordinary Skill (PHOSITA) Profile

A skilled professional with expertise in biomedical engineering, computer science, and healthcare information systems, possessing knowledge of medical data processing, AI applications in clinical decision support, and IoT-enabled medical monitoring technologies

Obviousness Rationale

A PHOSITA would recognize that the PTD's integration of blockchain, AI, and IoT technologies represents a predictable extension of the source patent's core insulin management methodology. The fundamental goal of improving insulin administration through digital technologies remains consistent, with the PTD merely applying known technological approaches to enhance the original system's capabilities. The combination of existing technologies to solve a known problem in medical data management would be considered an obvious iterative improvement by a skilled practitioner.

Obvious Combinations & Variations

Source Patent Element
Computer-implemented method for receiving sequential glucose measurements from electronic medical record systems
PTD Variation
Blockchain-based patient data management module with IoT-enabled continuous glucose monitoring
Obviousness Reasoning
A PHOSITA would find it obvious to enhance data storage and collection methods using blockchain and IoT technologies as predictable improvements to existing medical data management systems
Source Patent Element
Calculating insulin infusion rates based on sequential glucose measurements
PTD Variation
AI-driven clinical decision support system with machine learning-based predictive analytics
Obviousness Reasoning
Applying machine learning algorithms to optimize insulin dosing calculations represents a known technique for improving medical data processing and would be an obvious enhancement to existing insulin management methodologies
Source Patent Element
Electronic medical record integration for glucose measurement tracking
PTD Variation
Cloud-based data analytics platform with natural language processing for patient data analysis
Obviousness Reasoning
Integrating advanced data analysis techniques like NLP into medical record systems is a predictable evolution of existing health information technologies
Source Patent Element
Computer-implemented method for insulin administration management
PTD Variation
Wearable device with integrated IoT sensors and mobile app for patient engagement
Obviousness Reasoning
Extending medical monitoring technologies to patient-facing wearable devices represents a standard design choice for improving patient interaction and data collection
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857314 and the disclosed technological variations, a person of ordinary skill in the art would find the claimed innovations of the Intelligent Insulin Management Platform to be obvious extensions of existing insulin management methodologies. The combination of blockchain, AI, IoT, and cloud-based analytics represents predictable technological improvements that would be readily conceived by a skilled practitioner seeking to enhance medical data processing and patient monitoring systems.

Original Patent Information

Patent NumberUS 11,857,314
TitleInsulin management
Assignee(s)Aseko, Inc.